GLP1R and metabolic dysfunction-associated steatotic liver disease: Furthermore, GLP-1 RAs, along with pioglitazone, are denoted as the preferred agents for the treatment of hyperglycemia in adults with T2D and biopsy-proven NAFLD/MASLD or those at high risk for NAFLD/MASLD (Level of evidence A).